IDNA
iShares Genomics Immunology and Healthcare ETFIDNA Fund Description
IDNA tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering.
IDNA Factset Analytics Insight
IDNA holds a concentrated portfolio of global companies in the biopharmaceutical and healthcare equipment and services industries that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. In addition to these industry screens, companies must also meet certain size and liquidity measures for index eligibility. The underlying index then assigns a “Relationship Keyword Score” to each of the eligible companies using the FactSet Supply Chain Relationships database in search for keywords related to ‘Genomics and Immuno Biopharmaceutical’ products and technologies. The top 50 names with the highest scores are included in the index. Holdings are weighted by market-cap and are constrained such that no individual security exceeds 4% weight of the portfolio. The index rebalances semi-annually.
IDNA MSCI ESG Analytics Insight
iShares Genomics Immunology and Healthcare ETF has an MSCI ESG Fund Rating of BB based on a score of 5.40 out of 10. The MSCI ESG Fund Rating measures the resiliency of portfolios to long-term risks and opportunities arising from environmental, social, and governance factors. ESG Fund Ratings range from best (AAA) to worst (CCC). Highly rated funds consist of companies that tend to show strong and/or improving management of financially relevant environmental, social and governance issues. These companies may be more resilient to disruptions arising from ESG events.
The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. iShares Genomics Immunology and Healthcare ETF ranks in the 31st percentile within its peer group and in the 42nd percentile within the global universe of all funds covered by MSCI ESG Fund Ratings.
IDNA Summary Data
IDNA Portfolio Data
IDNA Index Data
IDNA Portfolio Management
IDNA Tax Exposures
IDNA Fund Structure
IDNA Factset Analytics Block Liquidity
This measurement shows how easy it is to trade a $1 million USD block of IDNA. IDNA is rated a 5 out of 5.
IDNA Tradability
IDNA Top 10 Holdings[View All]
IDNA Countries
IDNA
IDNA Regions
IDNA
IDNA Economic Development
IDNA
IDNA Performance Statistics
IDNA MSCI ESG Ratings
IDNA Benchmark Comparison Summary
IDNA
IDNA Benchmark Comparison Market Cap Size
IDNA
The data and information contained herein is not intended to be investment or tax advice. A reference to a particular investment or security, a credit rating, or any observation concerning a security or investment provided in the ETF.com Service is not a recommendation to buy, sell, or hold such investment or security or to make any other investment decisions. You should not use such information for purposes of any actual transaction without consulting an investment or tax professional.
ETF.com DOES NOT TAKE RESPONSIBILITY FOR YOUR INVESTMENT OR OTHER ACTIONS NOR SHALL ETF.com HAVE ANY LIABILITY, CONTINGENT OR OTHERWISE, FOR THE ACCURACY, COMPLETENESS, TIMELINESS, OR CORRECT SEQUENCING OF ANY INFORMATION PROVIDED BY ETF.com OR FOR ANY DECISION MADE OR ACTION TAKEN BY YOU IN RELIANCE UPON SUCH INFORMATION OR ETF.com.
[ETF.com DOES NOT PROVIDE ANY RESEARCH OPINIONS.] ETF.com MAKES NO REPRESENTATIONS ABOUT THE SUITABILITY OF THE INFORMATION, PRODUCTS OR SERVICES CONTAINED HEREIN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS.
Data provider:
Terms of Use
MSCI ESG Research LLC’s ("MSCI ESG") Fund Metrics products (the "Information") provide environmental, social and governance data with respect to underlying securities within more than 24,000 multi-asset class Mutual Funds and ETFs globally. MSCI ESG is a Registered Investment Adviser under the Investment Advisers Act of 1940. MSCI ESG materials have not been submitted to, nor received approval from, the US SEC or any other regulatory body. None of the Information constitutes an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product or trading strategy, nor should it be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. None of the Information can be used to determine which securities to buy or sell or when to buy or sell them. The Information is provided "as is" and the user of the Information assumes the entire risk of any use it may make or permit to be made of the Information.